European heart journal
-
European heart journal · Aug 2013
Randomized Controlled Trial Comparative StudyOutcomes of apixaban vs. warfarin by type and duration of atrial fibrillation: results from the ARISTOTLE trial.
It is uncertain whether the benefit from apixaban varies by type and duration of atrial fibrillation (AF). ⋯ The risks of stroke, mortality, and major bleeding were lower with apixaban than warfarin regardless of AF type and duration. Although the risk of stroke or systemic embolism was lower in paroxysmal than persistent or permanent AF, apixaban is an attractive alternative to warfarin in patients with AF and at least one other risk factor for stroke, regardless of the type or duration of AF.